Welcome to the 3rd Annual Gene Therapy for Blood Disorders
Uniting leading clinical, pre-clinical, translational, safety and commercial experts, the 3rd Gene Therapy for Blood Disorders Summit is the industry's definitive meeting focused on tackling the greatest challenges in drug development of gene therapy products.
Hear from the likes of the Pfizer, Expression, Jasper Therapeutics, BIOMARIN and more across 3 days of in-depth case studies, interactive panel discussions, dedicated Q+A time, and highly appraised in person networking opportunities to meet and learn from the leaders of this pioneering field.
Why Choose Us
Gene Therapies are set to revolutionize the therapeutic landscape for blood disorders. However, for the field to progress, there are several complex challenges unique to treating blood disorders that must be overcome.
To support rapidly evolving gene editing, in-vivo and ex-vivo gene therapy pipelines, the 3rd Gene Therapy for Blood Disorders will provide you with a 3-day comprehensive conference specifically designed for industry experts focused on all challenges from pre-clinical development through to commercial strategy.
With the news earlier this year that the FDA rejected BioMarin’s submission for approval, alongside a number of high profile safety cases it is clear that demonstrating durability and safety of doses must be achieved to progress gene therapy for blood disorders developers.
Join over 100 fellow industry experts from regulatory, clinical, commercial strategy, and patient-focused backgrounds, from established companies in the blood disorders space as well as the new companies on the block, to benchmark yourself against your competitors and overcome your clinical and commercial challenges to accelerate the development of your gene therapy to market.